Canaccord lowered the firm’s price target on Health Catalyst (HCAT) to $10 from $11 and keeps a Buy rating on the shares. The firm noted the company provided a slew of business updates last week, including an acquisition of a patient activation and engagement platform (Upfront Healthcare Services), a new multi-year platform client, a new partnership with Databricks to enhance the Ignite platforms data sharing and analytics capabilities, and preliminary 4Q results and updated targets for 2025 and long term (2028). Overall, the news created downward volatility due to high acquisition valuation and revenue growth lower than expected in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $7 from $9 at RBC Capital
- Health Catalyst to Acquire Upfront Healthcare Services
- Health Catalyst to acquire Upfront Healthcare Services, terms not disclosed
- Health Catalyst price target lowered to $10 from $10.50 at Citi
- Health Catalyst upgraded to Overweight from Sector Weight at KeyBanc